Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apraglutide in Hepatic Impairment
NCT05706623Phase 1Completed
- Sponsor
- VectivBio
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of apraglutide in short bowel syndrome (SBS) (3 arms), sponsored by VectivBio. Primary endpoints: Area Under the Curve to Infinity at Day 14, Area Under the Curve from Zero to 168 Hours and 1 more. Started Jan 2023; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT05706623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706623.